Pembrolizumab alone or in combination with chemotherapy versus chemotherapy for advanced gastric cancer: A cost-effectiveness analysis.

Lang, Yitian; Lin, Yan; Li, Dan; Liu, Jiyong; Liu, Xiaoyan

Lang, Yitian; Lin, Yan; Li, Dan; Liu, Jiyong; Liu, Xiaoyan.

Afiliación

Lang Y; Department of Pharmacy, Huangpu Branch, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lin Y; Department of Pharmacy, Huangpu Branch, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Li D; Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai, China.
Liu J; Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai, China.
Liu X; Department of Pharmacy, Huangpu Branch, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Cancer Med ; 12(18): 18447-18459, 2023 Sep.

Article en En | MEDLINE | ID: mdl-37706223

Palabras clave

advanced gastric cancer; cost-effectiveness; partitioned survival approach; pembrolizumab; the perspective of the US and China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Cancer Med Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google